These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37075722)

  • 1. Risk Factors of Capecitabine-Induced Hand-Foot Syndrome: A Single-Institution, Retrospective Study.
    Kanbayashi Y; Taguchi T; Ishikawa T; Otsuji E; Takayama K
    Oncology; 2023; 101(7):407-414. PubMed ID: 37075722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia.
    King TL; Voon PJ; Yuen KH; Mohamed Noor DA
    Support Care Cancer; 2024 May; 32(6):345. PubMed ID: 38743316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
    Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
    JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.
    Liao X; Huang L; Yu Q; He S; Li Q; Huang C; Yuan X
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):785-792. PubMed ID: 32193619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
    Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
    Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study).
    Iimura Y; Furukawa N; Ishibashi M; Ahiko Y; Tanabe T; Aikou S; Shida D; Nojima M; Kuroda S; Boku N
    BMC Gastroenterol; 2022 Jul; 22(1):341. PubMed ID: 35836104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer.
    Murugan K; Ostwal V; Carvalho MD; D'souza A; Achrekar MS; Govindarajan S; Gupta S
    Support Care Cancer; 2016 Jun; 24(6):2575-81. PubMed ID: 26715292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton Pump Inhibitors Ameliorate Capecitabine-induced Hand-Foot Syndrome in Patients With Breast Cancer: A Retrospective Study.
    Takemura M; Ikemura K; Yoshinami T; Toyozumi Y; Shintani T; Ueda M; Shimazu K; Okuda M
    Anticancer Res; 2022 May; 42(5):2591-2598. PubMed ID: 35489750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.
    Schmulenson E; Krolop L; Simons S; Ringsdorf S; Ko YD; Jaehde U
    Cancer Chemother Pharmacol; 2020 Sep; 86(3):435-444. PubMed ID: 32852627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a Novel Soaking Solution Used in Patients With Hand-Foot Syndrome as a Result of Capecitabine Treatment: A Randomized and Self-Controlled Trial.
    Xie Y; Wang Q; Hu T; Chen R; Wang J; Chang H; Peng X; Cheng J
    Clin Breast Cancer; 2022 Jul; 22(5):e685-e690. PubMed ID: 35354530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology.
    Anderson RT; Keating KN; Doll HA; Camacho F
    Oncologist; 2015 Jul; 20(7):831-8. PubMed ID: 26084809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
    Santhosh A; Sharma A; Bakhshi S; Kumar A; Sharma V; Malik PS; Pramanik R; Gogia A; Prasad CP; Sehgal T; Gund S; Dev A; Cheung WY; Pandey RM; Kumar S; Gupta I; Batra A;
    J Clin Oncol; 2024 May; 42(15):1821-1829. PubMed ID: 38412399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome.
    Huang XZ; Chen Y; Chen WJ; Zhang X; Wu CC; Wang ZN; Wu J
    Int J Cancer; 2018 Jun; 142(12):2567-2577. PubMed ID: 29355976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
    Pandy JGP; Franco PIG; Li RK
    Support Care Cancer; 2022 Nov; 30(11):8655-8666. PubMed ID: 35655045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102).
    Watanabe K; Ishibe A; Watanabe J; Ota M; Fujii S; Ichikawa Y; Oba MS; Endo I
    Indian J Gastroenterol; 2020 Apr; 39(2):204-210. PubMed ID: 32406009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
    Santhosh A; Kumar A; Pramanik R; Gogia A; Prasad CP; Gupta I; Gupta N; Cheung WY; Pandey RM; Sharma A; Batra A
    Trials; 2022 May; 23(1):420. PubMed ID: 35590388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized Trial.
    Andayani YD; Saleh MI; Sudoyo AW; Ali Z; Legiran L; Partan RU; Yuristo E; Lubis FZ
    Acta Med Indones; 2023 Oct; 55(4):396-402. PubMed ID: 38213043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03).
    Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Miura K; Oshio H; Ohori H; Ariyoshi K; Oyamada S; Iwase S
    Support Care Cancer; 2020 Aug; 28(8):3649-3657. PubMed ID: 31811480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemoglobin Value Is the Most Important Factor in the Development of Hand-Foot Syndrome under the Capecitabine Regimen.
    Naito M; Yamamoto T; Hara S; Shimamoto C; Miwa Y
    Chemotherapy; 2017; 62(1):23-29. PubMed ID: 27229894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a Structured Teaching Module Including Intensive Prophylactic Measures on Reducing the Incidence of Capecitabine-Induced Hand-Foot Syndrome: Results of a Prospective Randomized Phase III Study.
    Ostwal V; Kapoor A; Mandavkar S; Chavan N; Gupta T; Mirani J; Saklani A; Desouza A; Murugan K; Nashikkar C; Gupta S; Ramaswamy A
    Oncologist; 2020 Dec; 25(12):e1886-e1892. PubMed ID: 32717127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.